Core Viewpoint - Immunome, Inc. (IMNM) has seen a 19.1% increase in share price over the past four weeks, closing at $9.49, with analysts projecting a potential upside of 158.2% based on a mean price target of $24.50 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $5.76, indicating variability among analysts [2]. - The lowest price target of $20 suggests an 110.8% increase, while the highest target of $38 indicates a potential surge of 300.4% [2]. - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, four estimates have been revised upward, leading to a 14.8% increase in the Zacks Consensus Estimate for the current year [12]. - IMNM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13].

Group 1 - Shares of Quanex Building Products (NX) have increased by 7.5% over the past four weeks, closing at $20.19, with a mean price target of $37 indicating a potential upside of 83.3% [1] - The mean estimate includes three short-term price targets with a standard deviation of $5.57, where the lowest estimate of $31 suggests a 53.5% increase, and the highest estimate of $42 indicates a potential surge of 108% [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 2.8% over the past month [11][12] Group 2 - NX holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] - The clustering of price targets with a low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] - Despite skepticism around the reliability of price targets, the direction implied by them appears to be a useful guide for potential price movements [10]

Core Viewpoint - Perrigo (PRGO) shows potential for significant upside, with a mean price target of $36.67 indicating a 32.9% increase from the current price of $27.60 [1] Price Targets - The average price target consists of three estimates ranging from a low of $30 to a high of $42, with a standard deviation of $6.11, suggesting variability in analyst predictions [2] - The lowest estimate indicates an 8.7% increase, while the highest suggests a 52.2% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment - Analysts exhibit strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 0.1% over the past month, with no negative revisions [12] - PRGO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may be misleading, as analysts often set overly optimistic targets due to business incentives [8][10] - Empirical research indicates that price targets rarely predict actual stock price movements, suggesting a need for skepticism [7][10]

Core Viewpoint - Veris Residential (VRE) shares have shown a slight increase of 0.2% over the past four weeks, closing at $15.33, with a potential upside of 25.9% based on Wall Street analysts' mean price target of $19.30 [1][11]. Price Targets and Analyst Estimates - The mean estimate for VRE comprises five short-term price targets with a standard deviation of $4.02, indicating variability among analysts; the lowest estimate suggests a 4.4% increase to $16, while the highest predicts a surge of 69.6% to $26 [2][9]. - Analysts have recently shown increasing optimism regarding VRE's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has risen by 2.5% over the past month, with two estimates increasing and no negative revisions [12]. Analyst Behavior and Price Target Reliability - There is skepticism regarding the reliability of analysts' price targets, as empirical research indicates that these targets often mislead investors rather than provide accurate guidance [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations for stocks they cover [8]. - A low standard deviation in price targets suggests a high degree of agreement among analysts about the stock's price direction, serving as a starting point for further research [9]. Investment Ranking - VRE currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside in the near term [13].

Core Viewpoint - Glaukos (GKOS) shows potential for significant upside, with a mean price target of $128.54 indicating a 34.4% increase from the current price of $95.64, supported by positive earnings estimate revisions [1][11]. Price Targets - The average of 13 short-term price targets ranges from a low of $72 to a high of $182, with a standard deviation of $33.39, indicating variability in analyst estimates [2]. - The lowest estimate suggests a decline of 24.7%, while the most optimistic estimate indicates a potential upside of 90.3% [2]. Analyst Consensus - Analysts have shown strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11]. - The Zacks Consensus Estimate for the current year has increased by 11.8%, with four estimates moving higher and no negative revisions [12]. Zacks Rank - GKOS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Caution on Price Targets - Solely relying on price targets for investment decisions may be misleading, as analysts often set overly optimistic targets influenced by business relationships [3][8][10].

Group 1 - FuelCell Energy (FCEL) closed at $6.72, with a 57% gain over the past four weeks, and a mean price target of $9.38 indicating a 39.6% upside potential [1] - The average price targets range from a low of $5 to a high of $13.75, with a standard deviation of $3.19, suggesting variability in analyst estimates [2] - Analysts show strong agreement on FCEL's ability to report better earnings, with positive trends in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for FCEL has increased by 0.3% over the past month, indicating a positive outlook with no negative revisions [12] - FCEL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for potential price movements [13]

Core Viewpoint - Sangoma Technologies Corporation (SANG) shows potential for significant upside, with a mean price target of $8.42 indicating a 47.2% increase from the current price of $5.72 [1] Price Targets - The average price target consists of five estimates ranging from a low of $7.94 to a high of $9.50, with a standard deviation of $0.67, suggesting a consensus among analysts [2] - The lowest estimate indicates a potential increase of 38.8%, while the highest suggests a 66.1% upside [2] Analyst Sentiment - Analysts exhibit strong agreement on SANG's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 7.8%, with one estimate moving higher and no negative revisions [12] Zacks Rank - SANG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]

Group 1 - Alvotech (ALVO) shares have increased by 10.1% over the past four weeks, closing at $10.66, with a mean price target of $18.40 indicating a potential upside of 72.6% [1] - The average price targets range from a low of $14 to a high of $28, with a standard deviation of $5.73, suggesting a variability in estimates; the lowest estimate indicates a 31.3% increase, while the highest points to a 162.7% upside [2] - Analysts show a consensus that Alvotech will report better earnings than previously estimated, which is a positive indicator for potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for Alvotech's current year earnings has increased by 251.4% over the last 30 days, with two estimates moving higher and no negative revisions [12] - Alvotech holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]

Core Viewpoint - Concentra Group (CON) has seen a 2.9% increase in share price over the past four weeks, closing at $22.03, with a mean price target of $28 indicating a potential upside of 27.1% [1] Price Targets and Analyst Consensus - The average price target consists of eight estimates ranging from a low of $25 to a high of $30, with a standard deviation of $1.85, suggesting a potential increase of 13.5% to 36.2% from the current price [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about CON's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.5%, with three estimates moving higher and no negative revisions [12] Zacks Rank and Investment Potential - CON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside in the near term [13]

Group 1 - Birkenstock (BIRK) shares have increased by 4.1% over the past four weeks, closing at $54.76, with a mean price target of $68.88 indicating a potential upside of 25.8% [1] - The average of 17 short-term price targets ranges from a low of $57 to a high of $81, with a standard deviation of $7.34, suggesting a relatively high agreement among analysts [2] - Analysts are optimistic about BIRK's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for BIRK's current year earnings has increased by 4%, with eight estimates moving higher and one lower [12] - BIRK holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]